Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04323774 · ClinicalTrials.gov registry record · NA

Intervention For AYAS With Cancer Risk Syndromes

A NA study of Cancer Risk Syndrome, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
115
Enrollment target
5
Study locations

NCT04323774 is a NA study of Cancer Risk Syndrome that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 115 participants. The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04323774, a NA study of Cancer Risk Syndrome, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
115 participants
Enrollment target
5
Study locations

Study Summary

This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults. In this study, the investigators are looking at whether using a chatbot and online portal for cancer risk information helps improve communication and decision-making. * Over 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the U.S. every year and up to 10% have genetic changes (or, mutations) that put them at a higher risk of developing new cancers during their lifetimes. These genetic mutations can result in cancer risk syndromes (such as, Lynch Syndrome or Li-Fraumeni Syndrome). Identifying cancer risk syndromes can allow for screening and early diagnosis of future cancers, which could ultimately save lives and offer more care choices for patients. As a result, genetic counseling and testing for cancer risk syndromes is being recommended more for Adolescents and Young Adults with new cancer diagnoses, regardless of family history. * This research study to develop an intervention called AYA-RISE that aims to assist AYAs with cancer risk communication and decision-making around their caregivers.

Conditions Studied

Interventions

  • BEHAVIORAL AYA-RISE Adolescents and Young Adults Risk Information and Screening Education
  • BEHAVIORAL Standard clinical visit for genetic counseling

Study Locations (5)

Massachusetts

  • Boston Children's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Georgia

  • Emory University School of Medicine - Atlanta

Illinois

  • University of Chicago - Chicago

Utah

  • University of Utah, Huntsman Cancer Institute - Salt Lake City

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2021-03-01
Est. Completion 2027-06-30
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04323774

The ClinicalTrials.gov registry entry for NCT04323774 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer Risk Syndrome appearing as the primary indexed condition, and to 2 interventions - of which AYA-RISE Adolescents and Young Adults Risk Information and Screening Education is the first listed.

NCT04323774 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT04323774 about?

NCT04323774 is a clinical study titled "Intervention For AYAS With Cancer Risk Syndromes". This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults. In this study, the investigators are looking at whether using a chatbot and online portal for cancer risk information helps improve communication and decis...

What is the current status of trial NCT04323774?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 115 participants. The study started on 2021-03-01. Estimated completion is 2027-06-30.

What conditions does trial NCT04323774 study?

This clinical trial studies the following conditions: Cancer Risk Syndrome.

What interventions are being tested in trial NCT04323774?

The interventions under investigation include: AYA-RISE Adolescents and Young Adults Risk Information and Screening Education (BEHAVIORAL), Standard clinical visit for genetic counseling (BEHAVIORAL).

Who is sponsoring clinical trial NCT04323774?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04323774 being conducted?

This trial has 5 study locations across Georgia, Illinois, Massachusetts, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.